Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
38.93
+2.32 (6.34%)
At close: Sep 26, 2025, 4:00 PM EDT
38.95
+0.02 (0.05%)
After-hours: Sep 26, 2025, 7:39 PM EDT
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Agios Pharmaceuticals stock ranges from a low of $51 to a high of $65. The average analyst price target of $57 forecasts a 46.42% increase in the stock price over the next year.
Price Target: $57.00 (+46.42%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $56 | Strong Buy | Reiterates | $56 | +43.85% | Sep 4, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $71 → $65 | Buy | Maintains | $71 → $65 | +66.97% | Jul 28, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $52 → $51 | Strong Buy | Maintains | $52 → $51 | +31.00% | Jul 22, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $74 → $71 | Buy | Maintains | $74 → $71 | +82.38% | May 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $58 | Strong Buy | Reiterates | $58 | +48.99% | Feb 24, 2025 |
Financial Forecast
Revenue This Year
45.13M
from 36.50M
Increased by 23.66%
Revenue Next Year
109.97M
from 45.13M
Increased by 143.65%
EPS This Year
-7.56
from 11.64
EPS Next Year
-7.51
from -7.56
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 50.3M | 151.9M | |||
| Avg | 45.1M | 110.0M | |||
| Low | 39.2M | 75.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 37.8% | 236.6% | |||
| Avg | 23.7% | 143.7% | |||
| Low | 7.4% | 67.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.34 | -6.14 | |||
| Avg | -7.56 | -7.51 | |||
| Low | -7.53 | -9.15 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.